Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients under...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cells
Main Authors: Saltarella, Ilaria, Desantis, Vanessa, Melaccio, Assunta, Solimando, Antonio Giovanni, Lamanuzzi, Aurelia, Ria, Roberto, Storlazzi, Clelia Tiziana, Mariggiò, Maria Addolorata, Vacca, Angelo, Frassanito, Maria Antonia
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7017193/
https://ncbi.nlm.nih.gov/pubmed/31936617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9010167
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados